Back to search

Virginia Commonwealth University

Discovery of a Novel CCR5 Antagonist as an Effective Therapeutic Agent for Prostate Cancer

Abstract

dc:description.abstract

Previously, the CCR5 receptor was found to be a good target for treating prostate cancer (PCa). Dr. Yan Zhang’s laboratory designed several CCR5 antagonists, which were screened for their inhibitory effect on the growth and invasion of the M12, DU145 and PC-3 PCa cell lines. Primary in vitro screening showed one compound (Drug 17) significantly inhibited the proliferation of PCa cells at 1μM concentration, with a half-maximal inhibitory concentration of 237.68 nM. Further in vitro assays including a proliferation, cytotoxicity and invasion assay confirmed the inhibitory effect of drug 17. The physiological effect of drug 17 was tested by the Ware laboratory in vivo by subcutaneous injection of M12 cells into male, athymic nude mice. Tumor growth was slowed in mice receiving injections of drug 17 compared to sham injected controls. Thus, in vitro and in vivo assays suggest drug 17 might be an effective therapy to block PCa progression.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Physiology

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ahmed, Tasrif
Contributors dc:contributor
  • Zendra Zehner

Subjects

dc:subject × 15

Rights

dc:rights
Statement dc:rights
  • © The Author

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Ahmed, Tasrif. Discovery of a Novel CCR5 Antagonist as an Effective Therapeutic Agent for Prostate Cancer. Thesis thesis, https://doi.org/10.25772/E41B-1323